Sample ID:   

SRR10446261

Source Project ID:   

Cell Type:   

Primary B cell

Organism:   

Mus musculus

Strain:   

C57BL/6

Treatment:   

pre-Bortezomib + Etoposide

Treatment Time:   

Bortezomib was 1 hr prior to an additional 2 hrs co-treatment with  ETO

Treatment Dose:   

50uM Etoposide + 5uM Bortezomib

Genotype:   

WT

In-situ Treatment:   

Exo VII + Exo T

Cell Phase:   

G1

Spike-in Intensity:   

31.7215

Spike-in percentage:   

2.50%

Layout:   

SINGLE

Instrument model:   

Illumina NextSeq 550

Technique:   

END-seq

Fastqc: